001     154617
005     20240229123107.0
024 7 _ |a 10.1158/1055-9965.EPI-19-1545
|2 doi
024 7 _ |a pmid:32332031
|2 pmid
024 7 _ |a 1055-9965
|2 ISSN
024 7 _ |a 1538-7755
|2 ISSN
024 7 _ |a altmetric:80675502
|2 altmetric
037 _ _ |a DKFZ-2020-00890
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Butt, Julia Anna
|0 P:(DE-He78)31d7c3e829be03400641f80b821ef728
|b 0
|e First author
245 _ _ |a Antibody responses to Helicobacter pylori and risk of developing colorectal cancer in a European cohort.
260 _ _ |a Philadelphia, Pa.
|c 2020
|b AACR
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1635317138_24039
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2020 Jul;29(7):1475-1481.#EA:F022#LA:F022#
520 _ _ |a While Helicobacter pylori (H. pylori) is the major cause of gastric cancer, it has also been suggested to be involved in colorectal cancer (CRC) development. However, prospective studies addressing H. pylori and CRC are sparse and inconclusive. We assessed the association of antibody responses to H. pylori proteins with CRC in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort.We applied H. pylori multiplex serology to measure antibody responses to 13 H. pylori proteins in pre-diagnostic serum samples from 485 CRC cases and 485 matched controls nested within the EPIC study. Odds ratios (OR) and 95% confidence intervals (CI) were calculated using multivariable conditional logistic regression to estimate the association of H. pylori overall and protein-specific sero-positivity with odds of developing CRC.Fifty-one percent of CRC cases were H. pylori sero-positive compared to 44% of controls resulting in an OR of 1.36 (95% CI: 1.00-1.85). Among the 13 individual H. pylori proteins, the association was driven mostly by sero-positivity to Helicobacter cysteine-rich protein C (HcpC) (OR: 1.66, 95% CI: 1.19-2.30) and Vacuolating cytotoxin A (VacA) (OR: 1.34, 95% CI: 0.99-1.82), the latter being non-statistically significant only in the fully adjusted model.In this prospective multi-center European study, antibody responses to H. pylori proteins, specifically HcpC and VacA, were associated with an increased risk of developing CRC.Biological mechanisms for a potential causal role of H. pylori in colorectal carcinogenesis need to be elucidated, and subsequently whether H. pylori eradication may decrease CRC incidence.
536 _ _ |a 316 - Infections and cancer (POF3-316)
|0 G:(DE-HGF)POF3-316
|c POF3-316
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Jenab, Mazda
|b 1
700 1 _ |a Pawlita, Michael
|0 P:(DE-He78)d99bad949ba3ae93859eedae5ac266da
|b 2
700 1 _ |a Tjonneland, Anne
|0 0000-0003-4385-2097
|b 3
700 1 _ |a Kyrø, Cecilie
|0 0000-0002-9083-8960
|b 4
700 1 _ |a Boutron-Ruault, Marie-Christine
|0 0000-0002-5956-5693
|b 5
700 1 _ |a Carbonnel, Franck
|b 6
700 1 _ |a Dong, Catherine
|b 7
700 1 _ |a Kaaks, Rudolf
|0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
|b 8
700 1 _ |a Kühn, Tilman
|0 P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe
|b 9
700 1 _ |a Boeing, Heiner
|b 10
700 1 _ |a Schulze, Matthias B
|0 0000-0002-0830-5277
|b 11
700 1 _ |a Trichopoulou, Antonia
|b 12
700 1 _ |a Karakatsani, Anna
|0 0000-0002-3275-2026
|b 13
700 1 _ |a La Vecchia, Carlo
|0 0000-0003-1441-897X
|b 14
700 1 _ |a Palli, Domenico
|0 0000-0002-5558-2437
|b 15
700 1 _ |a Agnoli, Claudia
|b 16
700 1 _ |a Tumino, Rosario
|0 0000-0003-2666-414X
|b 17
700 1 _ |a Sacerdote, Carlotta
|b 18
700 1 _ |a Panico, Salvatore
|b 19
700 1 _ |a Bueno-de-Mesquita, Bas
|b 20
700 1 _ |a Vermeulen, Roel
|b 21
700 1 _ |a Gram, Inger T
|0 0000-0002-0031-4152
|b 22
700 1 _ |a Weiderpass, Elisabete
|0 0000-0003-2237-0128
|b 23
700 1 _ |a Benjaminsen Borch, Kristin
|0 0000-0002-1741-2322
|b 24
700 1 _ |a Quirós, J Ramón
|b 25
700 1 _ |a Agudo, Antonio
|b 26
700 1 _ |a Rodríguez-Barranco, Miguel
|0 0000-0002-9972-9779
|b 27
700 1 _ |a Santiuste, Carmen
|b 28
700 1 _ |a Ardanaz, Eva
|0 0000-0001-8434-2013
|b 29
700 1 _ |a Van Guelpen, Bethany
|0 0000-0002-9692-101X
|b 30
700 1 _ |a Harlid, Sophia
|0 0000-0001-8540-6891
|b 31
700 1 _ |a Imaz, Liher
|0 0000-0002-3777-4953
|b 32
700 1 _ |a Perez-Cornago, Aurora
|0 0000-0002-5652-356X
|b 33
700 1 _ |a Gunter, Marc J
|b 34
700 1 _ |a Zouiouich, Semi
|b 35
700 1 _ |a Park, Jin Young
|0 0000-0003-2491-5099
|b 36
700 1 _ |a Riboli, Elio
|b 37
700 1 _ |a Cross, Amanda J
|0 0000-0002-0893-2377
|b 38
700 1 _ |a Heath, Alicia K
|0 0000-0001-6517-1300
|b 39
700 1 _ |a Waterboer, Tim
|0 P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30
|b 40
|e Last author
700 1 _ |a Hughes, David J
|0 0000-0003-1668-8770
|b 41
773 _ _ |a 10.1158/1055-9965.EPI-19-1545
|g p. cebp.1545.2019 -
|0 PERI:(DE-600)2036781-8
|n 7
|p 1475-1481
|t Cancer epidemiology, biomarkers & prevention
|v 29
|y 2020
|x 1538-7755
909 C O |p VDB
|o oai:inrepo02.dkfz.de:154617
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)31d7c3e829be03400641f80b821ef728
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)d99bad949ba3ae93859eedae5ac266da
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 40
|6 P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-316
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Infections and cancer
|x 0
914 1 _ |y 2020
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CANCER EPIDEM BIOMAR : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 1 _ |0 I:(DE-He78)F022-20160331
|k F022
|l Infektionen und Krebs-Epidemiologie
|x 0
920 1 _ |0 I:(DE-He78)F020-20160331
|k F020
|l Infektionen und Krebs-Epidemiologie
|x 1
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 2
920 0 _ |0 I:(DE-He78)F022-20160331
|k F022
|l F022 Infektionen und Krebs-Epidemiologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)F022-20160331
980 _ _ |a I:(DE-He78)F020-20160331
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21